KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Shares Outstanding (Diluted Average): 2011-2025

Historic Shares Outstanding (Diluted Average) for Sarepta Therapeutics (SRPT) over the last 2 years, with Jun 2025 value amounting to $106.6 million.

  • Sarepta Therapeutics' Shares Outstanding (Diluted Average) rose 7.54% to $106.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $106.6 million, marking a year-over-year increase of 7.54%. This contributed to the annual value of $129.6 million for FY2011, which is N/A change from last year.
  • As of Q2 2025, Sarepta Therapeutics' Shares Outstanding (Diluted Average) stood at $106.6 million, which was up 6.15% from $100.4 million recorded in Q3 2024.
  • Sarepta Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $106.6 million for Q2 2025, and its period low was $88.7 million during Q2 2023.
  • For the 3-year period, Sarepta Therapeutics' Shares Outstanding (Diluted Average) averaged around $96.8 million, with its median value being $99.1 million (2024).
  • Data for Sarepta Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY grew of 13.00% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Sarepta Therapeutics' Shares Outstanding (Diluted Average) stood at $88.9 million in 2023, then climbed by 13.00% to $100.4 million in 2024, then grew by 7.54% to $106.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $106.6 million for Q2 2025, versus $100.4 million for Q3 2024 and $99.1 million for Q2 2024.